Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
-
LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
-
LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
-
Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11 First evidence of clinical...
-
Announced strategic acquisition of industry-leading Parkinson’s disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE ACI-24 full Phase 1b results...
-
ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS) Full Phase 1b results support the continued clinical development...
-
All-stock transaction maintains AC Immune’s strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune’s...
-
LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
-
Optimized vaccine candidate generates enhanced polyclonal antibody response against pyroglutamate Abeta in non-human primates Phase 2 interim analysis of ACI-24 confirms good safety and...
-
LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...